The wisdom of hormone-replacement therapy in survivors of ovarian and endometrial cancer

Surgical Clinics of North America

Volumn 81, Issue 4, 2001, Pages 987-993

  Lin, Kathleen ^a   Runowicz, Carolyn D ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

EID: 0035213941     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70177-8     Document Type: Article

References (34)

1. Estrogen-replacement therapy in patients with previous endometrial carcinoma
2. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women
3. Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma
4. A prospective cohort study of postmenopausal hormone use and risk of breast cancer in women
5. Nonhormonal alternatives to treating menopausal symptoms
6. Estrogen replacement in surgical stage I and II endometrial cancer survivors
7. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
8. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
9. Estrogen replacement therapy in the patient treated for endometrial cancer
10. Hormone replacement therapy and survival after surgery for ovarian cancer
11. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
12. Endometrial cancer in premenopausal women 45 years and younger
13. Hormone replacement therapy and endometrial cancer: Meta-analysis
14. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer
15. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial
16. Tubal ligation, hysterectomy, and risk of ovarian cancer
17. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study
18. Predominance of early endometrial cancers after long-term estrogen use
19. Hormone replacement therapy and endometrial cancer in Ontario, Canada
20. Review/hypothesis: Nutrition, hormones, and breast cancer: Is insulin the missing link?
21. Estrogen replacement therapy following treatment for stage I endometrial cancer
22. Oral contraceptives and the risk of hereditary ovarian cancer
23. Longer-term hormone replacement therapy and risk of breast cancer in postmenopausal women
24. Estrogen replacement therapy and risk of epithelial ovarian cancer
25. Estrogen replacement therapy and fatal ovarian cancer
26. The prevention of breast cancer through reduced ovarian steroid exposure
27. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
28. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
29. Endogenous estrogen and postmenopausal breast cancer: A quantitative review
30. Characteristics relating ovarian cancer risk: Collaborative analysis of 12 US case-control studies: II. Invasive epithelial ovarian cancers in white women
31. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
32. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy